R&D Executives Seek China Role In Clinical Development
What excites R&D heads and executives when it comes to China? Regulatory reforms, certainly, but emerging technologies including AI could position China for a bigger play, going by discussions at a recent forum that saw AstraZeneca, Sanofi, Beigene and Jiangsu Hengrui executives debate future biopharma development in China.
You may also be interested in...
2019 was the year that China approved the first new drug for Alzheimer's in nearly two decades and for the first US approval of an original cancer drug from China. While the simmering US trade war has been addressed by a phase one agreement to be signed, other uncertainties marked a year dominated by a large vaccine scandal and resulting bankruptcy, and increasing calls to include China in global clinical development plans.
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.